Skip to main content
SpringerLink
Log in

Comparison of first- and second-generation drug-eluting stent efficacies for treating left main and/or three-vessel disease: a propensity matched study

  • Original Article
  • Published:
Heart and Vessels Aims and scope Submit manuscript

Abstract

The efficacy of second-generation drug-eluting stent (DES) for the treatment of left main disease (LM) and/or three vessel disease (3VD) remains unclear. We compared 2-year outcomes of second- versus first -generation DES implantation among patients with LM and/or 3VD and to assess the differential of risk by complexity of coronary artery disease using synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) scores. Between April 2007 and December 2012, 341 patients with LM and/or 3VD were treated by percutaneous coronary intervention; 154 with first-generation DES and 137 with second-generation DES. After propensity matching, 101 patients remained in each group. The rate of target lesion revascularization (TLR) and major adverse cardiac event (MACE) were compared. TLR and MACE at 2 years were more common in the first- compared with second-generation DES group (TLR 19.8 vs. 8.9 %; p = 0.016, MACE 24.8 vs. 10.9 %; p = 0.008). In patients with low (0–22) and intermediate (23–32) SYNTAX scores, TLR and MACE tended to occur more often with first-generation DES group. In patients with high SYNTAX scores (≧33), TLR and MACE were significantly more common with first-generation DES group (TLR 29.0 vs. 11.1 %; p = 0.035, MACE 35.5 vs. 13.9 %; p = 0.034). Compared with first-generation DES, second-generation DES proved beneficial in reducing risk of TLR and MACE in patients with LM and/or 3VD, particularly among those with high SYNTAX scores (≧33).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R, Lesions RSGRSwtS-CBVB-ESitToPwdNNCA (2002) A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Eng J Med 346:1773–1780

    Article  CAS  Google Scholar 

  2. Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME, Investigators T-I (2004) A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Eng J Med 350:221–231

    Article  CAS  Google Scholar 

  3. Naito R, Miyauchi K, Konishi H, Tsuboi S, Ogita M, Kasai T, Tamura H, Okazaki S, Daida H (2015) Comparison of long-term clinical outcomes between sirolimus- and paclitaxel-eluting stents in real-world clinical practice. Heart Vessels 30:746–751

    Article  PubMed  Google Scholar 

  4. Yoshida T, Sakata K, Nitta Y, Taguchi T, Kaku B, Katsuda S, Shimojima M, Gamou T, Nakahashi T, Konno T, Kawashiri MA, Yamagishi M, Hayashi K (2015) Short- and long-term benefits of drug-eluting stents compared to bare metal stents even in treatment for large coronary arteries. Heart Vessel. doi:10.1007/s00380-015-0655-3

    Google Scholar 

  5. Park SJ, Kim YH, Park DW, Yun SC, Ahn JM, Song HG, Lee JY, Kim WJ, Kang SJ, Lee SW, Lee CW, Park SW, Chung CH, Lee JW, Lim DS, Rha SW, Lee SG, Gwon HC, Kim HS, Chae IH, Jang Y, Jeong MH, Tahk SJ, Seung KB (2011) Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Eng J Med 364:1718–1727

    Article  CAS  Google Scholar 

  6. Serruys PW, Onuma Y, Garg S, Vranckx P, De Bruyne B, Morice MC, Colombo A, Macaya C, Richardt G, Fajadet J, Hamm C, Schuijer M, Rademaker T, Wittebols K, Stoll HP (2010) 5-year clinical outcomes of the arts II (arterial revascularization therapies study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. J Am Coll Cardiol 55:1093–1101

    Article  PubMed  Google Scholar 

  7. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Stahle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW (2009) Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Eng J Med 360:961–972

    Article  CAS  Google Scholar 

  8. Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E, Colombo A, Mack MJ, Holmes DR Jr, Morel MA, Van Dyck N, Houle VM, Dawkins KD, Serruys PW (2013) Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical syntax trial. Lancet 381:629–638

    Article  PubMed  Google Scholar 

  9. Thygesen K, Alpert JS, White HD, Joint ESCAAHAWHFTFftRoMI, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, Simoons ML, Poole-Wilson PA, Gurfinkel EP, Lopez-Sendon JL, Pais P, Mendis S, Zhu JR, Wallentin LC, Fernandez-Aviles F, Fox KM, Parkhomenko AN, Priori SG, Tendera M, Voipio-Pulkki LM, Vahanian A, Camm AJ, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Morais J, Brener S, Harrington R, Morrow D, Lim M, Martinez-Rios MA, Steinhubl S, Levine GN, Gibler WB, Goff D, Tubaro M, Dudek D, Al-Attar N (2007) Universal definition of myocardial infarction. Circulation 116:2634–2653

    Article  PubMed  Google Scholar 

  10. Moynagh A, Salvatella N, Harb T, Darremont O, Boudou N, Dumonteil N, Lefevre T, Carrie D, Louvard Y, Leymarie JL, Chevalier B, Morice MC, Garot P (2013) Two-year outcomes of everolimus vs. paclitaxel-eluting stent for the treatment of unprotected left main lesions: a propensity score matching comparison of patients included in the french left main taxus (flm taxus) and the left main xience (lemax) registries. EuroIntervention 9:452–462

    Article  PubMed  Google Scholar 

  11. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH (2011) 2011 accf/aha/scai guideline for percutaneous coronary intervention: a report of the american college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation 124:e574–e651

    Article  PubMed  Google Scholar 

  12. Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS Jr, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW (2013) Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the spirit clinical trials program (clinical evaluation of the xience v everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). JACC Cardiovasc Interv 6:914–922

    Article  PubMed  Google Scholar 

  13. Kereiakes DJ, Sudhir K, Hermiller JB, Gordon PC, Ferguson J, Yaqub M, Sood P, Su X, Yakubov S, Lansky AJ, Stone GW (2010) Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the spirit III (a clinical evaluation of the investigational device xience v everolimus eluting coronary stent system [eecss] in the treatment of subjects with de novo native coronary artery lesions) and spirit IV (clinical evaluation of the xience v everolimus eluting coronary stent system in the treatment of subjects with de novo native coronary artery lesions) randomized trials. JACC Cardiovasc Interv 3:1229–1239

    Article  PubMed  Google Scholar 

  14. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC (2010) Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (compare): a randomised trial. Lancet 375:201–209

    Article  CAS  PubMed  Google Scholar 

  15. Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O’Shaughnessy C, Ball MW, Turco M, Applegate RJ, Gurbel PA, Midei MG, Badre SS, Mauri L, Thompson KP, LeNarz LA, Kuntz RE, EI Investigators (2006) Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 48:2440–2447

    Article  CAS  PubMed  Google Scholar 

  16. Kim JS, Jang IK, Fan C, Kim TH, Kim JS, Park SM, Choi EY, Lee SH, Ko YG, Choi D, Hong MK, Jang Y (2009) Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the endeavor oct trial. JACC Cardiovasc Interv 2:1240–1247

    Article  PubMed  Google Scholar 

  17. Wijns W, Steg PG, Mauri L, Kurowski V, Parikh K, Gao R, Bode C, Greenwood JP, Lipsic E, Alamgir F, Rademaker-Havinga T, Boersma E, Radke P, van Leeuwen F, Camenzind E, PS Committee Investigators (2014) Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the protect randomized trial. Eur Heart J 35:2812–2820

    Article  CAS  PubMed  Google Scholar 

  18. Kandzari DE, Leon MB, Meredith I, Fajadet J, Wijns W, Mauri L (2013) Final 5-year outcomes from the endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents. JACC Cardiovasc Interv 6:504–512

    Article  PubMed  Google Scholar 

  19. Cosgrave J, Corbett SJ, Melzi G, Babic R, Biondi-Zoccai GG, Airoldi F, Chieffo A, Sangiorgi GM, Montorfano M, Michev I, Carlino M, Colombo A (2007) Late restenosis following sirolimus-eluting stent implantation. Am J Cardiol 100:41–44

    Article  PubMed  Google Scholar 

  20. Park KW, Kim CH, Lee HY, Kang HJ, Koo BK, Oh BH, Park YB, Kim HS (2010) Does “late catch-up” exist in drug-eluting stents: insights from a serial quantitative coronary angiography analysis of sirolimus versus paclitaxel-eluting stents. Am Heart J 159(446–453):e3

    Google Scholar 

  21. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD (2004) Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109:701–705

    Article  PubMed  Google Scholar 

  22. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48:193–202

    Article  PubMed  Google Scholar 

  23. Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, Gold HK, Burke AP, Kolodgie FD, Virmani R (2008) Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation 118:1138–1145

    Article  PubMed  Google Scholar 

  24. Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y, Akasaka T, Igarashi K, Tanabe K, Morino Y, Ishikawa T, Nishikawa H, Awata M, Abe M, Okada H, Takatsu Y, Ogata N, Kimura K, Urasawa K, Tarutani Y, Shiode N, Kimura T, Investigators N (2013) Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. J Am Coll Cardiol 62:181–190

    Article  CAS  PubMed  Google Scholar 

  25. Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, Rademaker-Havinga T, van Es GA, Meier B, Juni P, Windecker S (2013) Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the leaders (limus eluted from a durable versus erodable stent coating) randomized, noninferiority trial. JACC Cardiovasc Interv 6:777–789

    Article  PubMed  Google Scholar 

  26. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van’t Veer M, Klauss V, Manoharan G, Engstrom T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF, Investigators FS (2009) Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Eng J Med 360:213–224

    Article  CAS  Google Scholar 

  27. Pijls NH, Fearon WF, Tonino PA, Siebert U, Ikeno F, Bornschein B, van’t Veer M, Klauss V, Manoharan G, Engstrom T, Oldroyd KG, Ver Lee PN, MacCarthy PA, De Bruyne B, Investigators FS (2010) Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the fame (fractional flow reserve versus angiography for multivessel evaluation) study. J Am Coll Cardiol 56:177–184

    Article  PubMed  Google Scholar 

  28. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS, Group CTR (2007) Optimal medical therapy with or without pci for stable coronary disease. N Eng J Med 356:1503–1516

    Article  CAS  Google Scholar 

  29. Pijls NH, van Schaardenburgh P, Manoharan G, Boersma E, Bech JW, van’t Veer M, Bar F, Hoorntje J, Koolen J, Wijns W, de Bruyne B (2007) Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the defer study. J Am Coll Cardiol 49:2105–2111

    Article  PubMed  Google Scholar 

  30. Nam CW, Mangiacapra F, Entjes R, Chung IS, Sels JW, Tonino PA, De Bruyne B, Pijls NH, Fearon WF, Investigators FS (2011) Functional syntax score for risk assessment in multivessel coronary artery disease. J Am Coll Cardiol 58:1211–1218

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, 3-6-1 Shimosueyoshi, Tsurumi-ku, Yokohama, Kanagawa, 230-8765, Japan

    Norihiro Kobayashi, Yoshiaki Ito, Keisuke Hirano, Masahiro Yamawaki, Motoharu Araki, Tsuyoshi Sakai, Hideyuki Takimura, Yasunari Sakamoto, Shinsuke Mori, Masakazu Tsutsumi, Takuro Takama, Hiroya Takafuji, Takashi Maruyama, Yohsuke Honda, Takahiro Tokuda, Kenji Makino, Shigemitsu Shirai & Toshiya Muramatsu

Authors
  1. Norihiro Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshiaki Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keisuke Hirano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masahiro Yamawaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Motoharu Araki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tsuyoshi Sakai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hideyuki Takimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yasunari Sakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shinsuke Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masakazu Tsutsumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Takuro Takama
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hiroya Takafuji
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Takashi Maruyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Yohsuke Honda
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Takahiro Tokuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Kenji Makino
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Shigemitsu Shirai
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Toshiya Muramatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Norihiro Kobayashi.

Ethics declarations

Conflict of interest

The authors report no financial relationships or conflicts of interest regarding the content herein.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kobayashi, N., Ito, Y., Hirano, K. et al. Comparison of first- and second-generation drug-eluting stent efficacies for treating left main and/or three-vessel disease: a propensity matched study. Heart Vessels 31, 1930–1942 (2016). https://doi.org/10.1007/s00380-016-0824-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00380-016-0824-z

Keywords

Search

Navigation